In the Editorial entitled "Understanding Parkinson Disease" published
in the January 27, 1999, issue of THE JOURNAL (1999;281:376-378), selegiline
was identified as an MAO type A inhibitor rather than a type B inhibitor.
On page 377, the sentence should have read, "Selegiline is a monoamine oxidase
type B inhibitor that limits the formation of free radicals derived from oxidation
of dopamine, and application of this agent in clinical trials suggests an
effect on disease progression consistent with a neuroprotective action.23-25"
Author Omitted. JAMA. 1999;282(1):29. doi:10.1001/jama.282.1.29